SCHEDULE 13G/A 0001781002-24-000025 0001781002 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 09/30/2024 0001645460 Cue Biopharma, Inc. 22978P106 40 Guest Street Boston MA 02135 Rule 13d-1(b) Bleichroeder LP DE 6127662 0 6127662 0 6127662 N 9.99 IA Relating to item 11 on this page: Based on 60,207,717 shares reported by the Issuer to be outstanding plus 1,130,422 shares of Common Stock underlying warrants held by the Reporting Persons Bleichroeder Holdings LLC DE 6127662 0 6127662 0 6127662 N 9.99 HC Relating to item 11 on this page: Based on 60,207,717 shares reported by the Issuer to be outstanding plus 1,130,422 shares of Common Stock underlying warrants held by the Reporting Persons Cue Biopharma, Inc. 40 Guest Street, Boston, MA 02135 Bleichroeder Holdings LLC Bleichroeder LP 1345 Avenue of the Americas, 47th Floor New York, NY 10105 Delaware, USA N IA HC See cover page. See cover page. See cover page. See cover page. See cover page. See cover page. Y N N Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 6,127,662 shares, or 9.99%, of the common stock ("Common Stock") reported by the Issuer as outstanding. Bleichroeder is the beneficial owner of Common Stock, warrants with a 4.99% limit on the exercise of such warrants, warrants with a 9.99% limit on the exercise such such warrants, and pre-funded warrants with a 9.99% limit on the exercise such such warrants. If there was no 4.99% limit on the exercise of certain warrants, nor a 9.99% limit on the exercise of certain warrants and and pre-funded warrants, Bleichroeder would be deemed to be the beneficial owner of 4,997,240 shares of Common Stock, 306,278 shares of Common Stock issuable upon exercise of the warrants subject to a 4.99% limit, 1,250,000 shares of Common Stock issuable upon exercise of the warrants subject to a 9.99% limit, and 2,964,366 shares of Common Stock issuable upon exercise of the pre-funded warrants subject to a 9.99% limit, representing 14.7% of the outstanding shares of Common Stock. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. N See exhibit 99.1 Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Subsidiary Information Bleichroeder LP Michael M. Kellen 10/07/2024 Bleichroeder Holdings LLC Michael M. Kellen 10/07/2024